The Hsp90 inhibitor 17-AAG promotes hepatic albumosomal accumulation in vitro and in vivo, through which suppressing the progression of NAFLD in mice. The gene discussed is HSP90AB1; the disease is metabolic dysfunction-associated steatotic liver disease.